Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|9|701-707

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.9, 2015-09, pp. : 701-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Telaprevir‐based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1076-1085

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 8, 2015-08 ,pp. : 1309-1316

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 7, 2015-07 ,pp. : 745-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C Virus

By  

Oncology, Vol. 87, Iss. 1, 2014-11 ,pp. : 110-117

Karger

Access to resources Recommend Favorite

TE predicts liver fibrosis of CHB in China

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 4, 2015-04 ,pp. : 756-762

John Wiley & Sons Inc

Access to resources Recommend Favorite